-- 
FDA Committee Discusses Teva's Azilect (Part 3)

-- B y  
-- 
2011-10-17T22:36:44Z

-- http://www.bloomberg.com/news/2011-10-17/fda-committee-discusses-teva-s-azilect-part-3-video-.html
A U.S. Food and Drug Administration 
advisory committee meets to discuss a supplemental new drug 
application for Teva Pharmaceutical Inc.'s Azilect, for the 
proposed indication of treating patients with idiopathic (of 
unknown cause) Parkinson's disease to slow clinical progression 
and treat the symptoms of the disease as initial monotherapy and
as adjunct therapy to levodopa. (This report is an excerpt and 
the third part of the meeting. Source: Bloomberg)  Running time 02:03:02
 